Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.
Redx Pharma Plc is pleased to announce that it will present data on its novel bacterial topoisomerase inhibitors (NBTIs) at the inaugural annual American Society for Microbiology (ASM) Microbe 2016 conference taking place from 16-20 June in Boston, Massachusetts.
Both the rise of antimicrobial resistance and the current antibiotic innovation gap have highlighted the need for novel antimicrobial agents, particularly for the treatment of Gram-negative bacterial infections. Redx is making promising progress in meeting this need following its discovery of a series of NBTIs that demonstrate broad-spectrum antibacterial activity against ESKAPE pathogens and low potential for resistance development.
Redx will be presenting the in vitro biological properties of its NBTIs, including activity against multi-drug resistant strains, preliminary assessment of safety profile and data on the in vivo exposure level of representative compounds.
As a fast-growing dynamic business we are continually looking for talented people to join our team.
Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.
Modulating the immune system with novel small molecules to treat a range of diseases with high unmet medical need.
Delivering multiple development candidates across a range of mechanistic approaches in cancer treatment.